Literature DB >> 18846001

Re-irradiation of head and neck carcinoma.

William M Mendenhall1, Charles M Mendenhall, Robert S Malyapa, Jatinder R Palta, Nancy P Mendenhall.   

Abstract

To determine the efficacy of re-irradiation of patients with head and neck carcinoma we reviewed the pertinent literature. Depending on the location and extent of the tumor, re-irradiation may be accomplished with external beam radiotherapy (RT), brachytherapy, intraoperative RT, and/or radiosurgery. The likelihood of cure is impacted by the interval between the initial course of RT and re-irradiation, whether the carcinoma is a recurrence or a second primary tumor, initial T-stage, and recurrent T-stage (rT-stage), whether the gross disease is isolated or local-regional, and histology. Patients with T1-T2 N0 second primary tumors have a relatively high likelihood of cure, whereas those with recurrent T3-T4 cancers, a short disease-free interval, and/or associated with a regional recurrence have a very low probability of cure. The likelihood of severe late complications is relatively high and is related to prior RT dose, primary site, retreatment RT dose, treatment volume, and technique. Previously irradiated patients with T1-T2 N0 carcinomas who are not surgical candidates may benefit from re-irradiation, albeit with an elevated risk of late complications. Those with advanced recurrences are unlikely to benefit from re-irradiation and should be considered for either a prospective clinical trial or for palliative chemotherapy or supportive care.

Entities:  

Mesh:

Year:  2008        PMID: 18846001     DOI: 10.1097/COC.0b013e3181637398

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  20 in total

1.  When is re-irradiation in head and neck squamous cell carcinoma not indicated?

Authors:  Primož Strojan; Jonathan J Beitler; Carl E Silver; William M Mendenhall; Ashok R Shaha; Alessandra Rinaldo; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-09       Impact factor: 2.503

2.  Surface markers for guiding cylindrical diffuser fiber insertion in interstitial photodynamic therapy of head and neck cancer.

Authors:  Emily Oakley; David A Bellnier; Alan Hutson; Brian Wrazen; Hassan Arshad; Harry Quon; Gal Shafirstein
Journal:  Lasers Surg Med       Date:  2017-02-10       Impact factor: 4.025

3.  Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma.

Authors:  Filippo Alongi; Elena Clerici; Sara Pentimalli; Pietro Mancosu; Marta Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2012-08-10

4.  Re-irradiation with curative intent in patients with squamous cell carcinoma of the head and neck: a national survey of usual practice on behalf of the Italian Association of Radiation Oncology (AIRO).

Authors:  Marta Maddalo; Pierluigi Bonomo; Liliana Belgioia; Almalina Bacigalupo; Vittorio Donato; Daniela Alterio; Ester Orlandi; Angela Argenone; Anna Merlotti; Daniela Musio; Marianna Trignani; Stefano Ursino; Stefano Arcangeli; Carlo Furlan; Mattia Falchetto Osti
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-26       Impact factor: 2.503

5.  Disease course after the first recurrence of head and neck squamous cell carcinoma following (chemo)radiation.

Authors:  Mischa de Ridder; Pieter D de Veij Mestdagh; Joris B W Elbers; Arash Navran; Charlotte L Zuur; Ludi E Smeele; Abrahim Al-Mamgani
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-10       Impact factor: 2.503

6.  Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems.

Authors:  Zachary S Morris; Jamey P Weichert; Jarob Saker; Eric A Armstrong; Abigail Besemer; Bryan Bednarz; Randall J Kimple; Paul M Harari
Journal:  Radiother Oncol       Date:  2015-06-26       Impact factor: 6.280

7.  Dose Response of MTLn3 Cells to Serial Dilutions of Arsenic Trioxide and Ionizing Radiation.

Authors:  Waseem Khan Raja; Jahangir Satti; Gang Liu; James Castracane
Journal:  Dose Response       Date:  2011-09-29       Impact factor: 2.658

8.  The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer.

Authors:  Mohamedtaki A Tejani; Roger B Cohen; Ranee Mehra
Journal:  Biologics       Date:  2010-08-09

Review 9.  Reirradiation of head and neck cancer focusing on hypofractionated stereotactic body radiation therapy.

Authors:  Hideya Yamazaki; Naohiro Kodani; Mikio Ogita; Kengo Sato; Kengo Himei
Journal:  Radiat Oncol       Date:  2011-08-21       Impact factor: 3.481

10.  A retrospective study of head and neck re-irradiation for patients with recurrent or second primary head and neck cancer: the McGill University experience.

Authors:  Rolina Al-Wassia; Siavosh Vakilian; Crystal Holly; Khalil Sultanem; George Shenouda
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.